In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard R. Furman argues that CR and MRD negativity is no longer required for treatment of CLL in the era of novel agents.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204
© 2016 Imedex, LLC.
Advertisement